Skip to content Skip to footer
Subscribe Now
INSIGHTS+

Most Viewed Articles of 2024 

2024, remained a busy year for PharmaShots. To keep our readers up to date on the developments in the healthcare sector, PharmaShots worked steadfastly to deliver real-time and real-world updates. Here’s a synopsis of our key reports and most-read news of the year.      Top 20 Medical Device Companies of 2024   Shots:    Bringing innovation and technology to healthcare, the…
January 2, 2025

Read more

New Drug Designations - November 2024
INSIGHTS+

New Drug Designations – November 2024

Shots:   PharmaShots' designation report provides a concise overview of the latest drug designations by major regulatory authorities, including the FDA, EMA, and NMPA   The November 2024 report covers designations granted to 28 drugs and 3 devices, encompassing 9 small molecules, 6 biologics, 7 cell and gene therapies as well as 3 medical devices  Significant trends…
December 31, 2024

Read more

Viewpoints_Jay Anders
VIEWPOINTS

Fostering Safe AI Use: Jay Anders from Medicomp in a Riveting Conversation with PharmaShots

Shots:  Nearly half of FDA-approved AI medical devices lack testing on real patient data, raising significant concerns about patient safety.  PharmaShots welcomes Jay Anders, CMO of Medicomp Systems, to discuss AI implementation trends in healthcare and strategies for ethical AI adoption by healthcare professionals.  Jay emphasizes the importance of clinical validations to ensure the safe…
December 23, 2024

Read more

Viewpoints_Mark Genovese 
VIEWPOINTS

Lilly at UEGW 2024: Mark Genovese in an Illuminating Dialogue Exchange with PharmaShots shares insights into VIVID-1 study

Shots:  Recently, at UEGW 2024, Lilly presented histologic and combined histologic-endoscopic outcomes from the VIVID-1 Phase III study, which evaluated the safety and efficacy of mirikizumab in adults with moderately to severely active Crohn’s disease  A key finding reported during UEG Week highlighted the interactions between mirikizumab and ustekinumab, particularly regarding histologic response and remission,…
December 18, 2024

Read more

PharmaShots Magazine-December 2024 Edition
MAGAZINE

PharmaShots Magazine-December 2024 Edition

Do you know that several European countries offer European Health Insurance Cards that allow citizens to seek emergency care when they travel? European countries are widely regarded for their superior quality healthcare services. With most European countries offering Universal Coverage for primary care, this magazine aims to navigate the nuances of the European Healthcare System. …
December 11, 2024

Read more

Key Biosimilars Events of November 2024
INSIGHTS+

Key Biosimilars Events of November 2024

Shots:       Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency        Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients        A major highlight was the EC’s approval of Sandoz’ Afqlir for treating…
December 3, 2024

Read more

Viewpoints_Marcelo Freire
VIEWPOINTS

Takeda at UEG Week 2024: Marcelo Freire from Takeda in an Enlightening Conversation with PharmaShots

Shots:  Recently, Takeda shared 32-week interim results from the VERDICT study, which evaluated Entyvio (vedolizumab) for the treatment of patients with ulcerative colitis (UC)  Entyvio achieved a stringent endpoint of disease clearance, a new concept in UC clinical research, which is a combination of clinical, endoscopic, and histologic remission  Today at PharmaShots, we are joined…
December 2, 2024

Read more

Viewpoints_John Santini
VIEWPOINTS

Fluorescence Visualization in Lung Cancer: John Santini from Vergent Bioscience in Conversation with PharmaShots

Shots:  With the growing significance of minimally invasive surgery comes the need for enhanced visualization to optimize surgical outcomes for both surgeons and patients.  Vergent BioScience’s VGT-309 shows promising potential for tumor visualization during lung cancer surgeries. VGT-309 is an investigational intraoperative molecular imaging (IMI) agent that utilizes near-infrared (NIR) fluorescence imaging to improve precision. …
November 25, 2024

Read more

Load more